TScan Therapeutics' departing CEO David Southwell and CSO/COO Gavin MacBeath
TCR upstart announces CEO exit, with CSO now acting replacement
A public T cell biotech’s chief executive has decided to leave the company.
TScan Therapeutics said Friday morning that CEO David Southwell stepped down earlier this week, leaving both his chief executive and board member roles. Filling in is Gavin MacBeath, the company’s CSO and COO. He became the acting CEO on Tuesday, and will continue to remain CSO and COO, TScan’s announcement read.
Southwell didn’t reveal what his next steps are, saying in prepared remarks only that he looks forward to following the company as “I move on to other opportunities.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters